Biotech Values

[DewDiligence]

EPIX -34% on drawn-out phase-1 schedule:

https://finance.yahoo.com/news/essa-pharma-provides-corporate-reports-110000611.html

…we plan to enroll additional higher dose cohorts using a twice daily (BID) dosing schedule to further enhance patient drug exposures. In addition, we are planning to file a protocol amendment to focus further monotherapy development in less heavily pretreated patients in whom we believe the androgen receptor pathway continues to be the primary driver of tumor growth. Our goal is to establish a recommended Phase 2 dose ("RP2D") for monotherapy during the first half of 2022… We look forward to presenting a clinical readout of the Phase 1a monotherapy trial in the first half of 2022.